[{"orgOrder":0,"company":"Oyagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sangivamycin Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oyagen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oyagen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oyagen \/ Not Applicable"},{"orgOrder":0,"company":"Oyagen","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Sangivamycin Hydrochloride","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oyagen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oyagen \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Oyagen \/ Tonix Pharmaceuticals"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"University of Alberta","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Sangivamycin Hydrochloride","moa":"Wnt\/Beta-Catenin signaling pathway","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ University of Alberta","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ University of Alberta"}]

Find Clinical Drug Pipeline Developments & Deals for Sangivamycin Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The research collaboration is focused on the development and testing of TNX-3500 (sangivamycin), Wnt/β-Catenin signaling pathway inhibitors as broad-spectrum antivirals against SARS-CoV-2 and other emerging viruses.

                          Brand Name : TNX-3500

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 18, 2022

                          Lead Product(s) : Sangivamycin Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : University of Alberta

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the terms of the agreement, Tonix has been granted an exclusive license from OyaGen for technology and patents related to TNX-3500 and other related compounds.

                          Brand Name : TNX-3500

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 19, 2021

                          Lead Product(s) : Sangivamycin Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Tonix Pharmaceuticals Holding Corp

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The study results showed that OYA1 was "highly effective" in reducing the spread of Ebola Virus infection in laboratory tests with the live Ebola virus carried out by NIAID. The data also suggest that OYA1 could be significantly more potent than Gilead ...

                          Brand Name : OYA1

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 07, 2021

                          Lead Product(s) : Sangivamycin Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank